Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Nasdaq: CRBP · Pharmaceutical Preparations · Norwood, MA · filing with the SEC since 2014

Full chart Alerts Compare

Grade4.7

◀ Past 2.6● Present 5.1▶ Future 5.7

4 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2022, as filed

Revenue$0.00-100.0%

Net income-$42.3M+7.2%

Earnings per share$-10.15+9.0%

Operating cash flow-$37.5M+22.1%

Cash$17.0M-32.0%

Debt$21.6M+1.9%

Shareholders’ equity$33.0M-52.3%

Shares, diluted4,170,675+1.8%

Return on equity-53.2%

The recordfrom its filings

Filings in 202674

Newest filingNov 10 · 10-Q

Annual reportMar 9, 2026

Quarterly reportNov 10, 2026

Next report due10-K by Mar 31

Insider sales, 12 months$600,000

Insider buys, 12 months$100,000

Patents granted6

Filer categoryNon-accelerated filer<br>Smaller reporting company

Trailing twelve months to Sep 2026Net income -$116MCash from operations -$92.4Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

16171819202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Nov 10, 2026 · SEC EDGAR · Form 8-K

Results released

Open the filing on sec.gov

Nov 2, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Nov 2, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Oct 29, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Oct 15, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Sep 30, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Sep 15, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Sep 14, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Aug 17, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Corbus Pharmaceuticals Holdings, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Norwood, MA.

Newest on the record

Quarterly report on Nov 10. Before it, current report on Nov 10.

What is due next

The 10-K for the period to Dec 31, 2026, due by Mar 31, 2027.

About CRBP

Corbus Pharmaceuticals Holdings, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Norwood, MA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported a loss of $79 million (its filed statements).

IndustryPharmaceutical Preparations

HeadquartersNorwood, MA

Business modelPre-revenue company

ExchangeNasdaq

Filing since2014

Fiscal year endsDec 31

SEC number (CIK)1595097

Peers on fileCLYM, ELDN, APUS, CYPH

Who runs it

Financial performance

In fiscal 2022 Corbus Pharmaceuticals Holdings’s revenue was $0, down 100.0% from $881,705 the year before. It made a net loss of $42.35 million.

Annual report, filed Mar 9, 2026.

Financial statements

The grade

Corbus Pharmaceuticals Holdings grades 4.7 of 10 against its own industry, the 497 companies in Pharmaceutical Preparations. Five of the nine metrics are read as filed and four are SI estimates, each with its reasoning.

◀ Past2.6

● Present5.1

▶ Future5.7

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton CRBP · research, not advice